# FDA Grants Breakthrough Therapy Designation to VERTANICAL’s VER-01 for Chronic Low Back Pain > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/breakthrough-therapy-chronic-low-back-pain-fda-designation/ > **Published:** 2026-05-24T23:55:05-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:53:53-04:00 > **Clinical Summary:** FDA breakthrough therapy chronic low back pain designation for VER-01 offers hope for non-opioid cannabis-derived treatment advancing clinical development. --- ✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PainResearchPolicyIndustryNeurologySafetyBreakthrough Therapy Clinical Summary # Clinical Summary The FDA’s Breakthrough Therapy designation for VER-01 represents an expedited regulatory pathway for a cannabis-derived treatment targeting chronic low back pain, a condition affecting millions of patients and contributing substantially to opioid prescribing and healthcare costs. This designation indicates that preliminary evidence suggests VER-01 may demonstrate substantial improvement over existing therapies, potentially offering a non-opioid alternative for a major source of chronic pain. The designation will accelerate clinical development and FDA review timelines, potentially bringing this candidate to market faster than the standard regulatory process would allow. For clinicians managing chronic low back pain, this development signals emerging pharmaceutical-grade cannabis options that undergo rigorous efficacy and safety testing, contrasting with unregulated cannabis products currently available to patients. Patients may gain access to a standardized, FDA-approved [cannabis-based medicine](https://cedclinic.com/former-nfl-quarterback-urges-athletes-to-consider-cbd-products/) with defined dosing and quality assurance rather than relying on variable products from the unregulated market. Clinicians should monitor the progress of VER-01 through [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and FDA review, as approval could expand the evidence-based pharmaceutical toolkit for [chronic pain management](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) and potentially reduce reliance on opioids in this population. Dr. Caplan’s Take “The FDA’s breakthrough designation for VER-01 represents exactly the kind of clinical validation our patients deserve, because it means we’re finally moving cannabis therapeutics through the same rigorous scrutiny we apply to any other medicine rather than treating it as categorically different.” Clinical Perspective The FDA’s Breakthrough Therapy designation for VER-01 in chronic low back pain represents an important regulatory signal that cannabinoid-based therapeutics are advancing through formal clinical pathways, potentially offering an alternative for patients with limited options or intolerance to conventional analgesics. However, clinicians should interpret this designation cautiously, as it reflects promising early data rather than proven efficacy or safety in larger populations, and the full [clinical trial results](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/) remain pending. The heterogeneity of cannabis preparations, dosing regimens, and patient populations across studies makes it difficult to generalize findings to routine clinical practice, and long-term safety data on cannabinoid use remain limited compared to established pain management options. Until phase 3 data and regulatory approval are complete, providers caring for patients with chronic low back pain should continue following evidence-based guidelines prioritizing multimodal approaches including physical therapy and judicious opioid use, while remaining aware that 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/pain-management/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20FDA%20Grants%20Breakthrough%20Therapy%20Designation%20to%20VERTANICAL%27s%20VER-01%20for%20Chronic%20Low%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56460)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56460)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20FDA%20Grants%20Breakthrough%20Therapy%20Designation%20to%20VERTANICAL%27s%20VER-01%20for%20Chronic%20Low%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56460)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://hempgazette.com/news/fda-grants-breakthrough-therapy-designation-vertanicals-ver01-chronic-low-back-p/](https://hempgazette.com/news/fda-grants-breakthrough-therapy-designation-vertanicals-ver01-chronic-low-back-p/) Further Reading Evidence Watch[Cannabis Use in Pregnancy Linked to Child Behavioral Outcomes: A Study on Autism Spectrum Disorder](https://cedclinic.com/peripregnancy-cannabis-exposure-child-development/) CED Clinic Blog[The First Cannabis Drug to Earn FDA Breakthrough Therapy Status for Pain`](https://cedclinic.com/fda-breakthrough-therapy-ver-01-cannabis-chronic-back-pain/) Cannabis Policy WireCED Regulatory Digest, Since Last Digest, 1 items [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [The Realities of Rescheduling Medical Cannabis | Rockefeller Institute of Government](https://cedclinic.com/the-realities-of-rescheduling-medical-cannabis-rockefeller-institute-of-government/) Explore the challenges and impacts of medical cannabis rescheduling on research and patient access. [Read More](https://cedclinic.com/the-realities-of-rescheduling-medical-cannabis-rockefeller-institute-of-government/) [Clinical Trial: High Doses of CBD Superior to Placebo in Treating Neuropathic Pain](https://cedclinic.com/clinical-trial-high-doses-of-cbd-superior-to-placebo-in-treating-neuropathic-pain/) Review recent clinical evidence supporting high-dose CBD for neuropathic pain management. [Learn More](https://cedclinic.com/clinical-trial-high-doses-of-cbd-superior-to-placebo-in-treating-neuropathic-pain/) [Ananda Pharma Confirms Safety of MRX1 CBD Drug, as Clinical Pain Trials Approach](https://cedclinic.com/ananda-pharma-confirms-safety-of-mrx1-cbd-drug-as-clinical-pain-trials-approach/) Insights into the safety profile of a promising CBD drug nearing [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) for pain relief. [Discover More](https://cedclinic.com/ananda-pharma-confirms-safety-of-mrx1-cbd-drug-as-clinical-pain-trials-approach/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).